Skip to main content
Premium Trial:

Request an Annual Quote

Intomics Collaborates with Lundbeck

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danish bioinformatics and systems biology firm Intomics said today that H. Lundbeck will use its research services for data analysis and integration in its drug development process.

Under the agreement, Intomics will provide Lundbeck with data analysis and systems biology expertise, methods, and tools for analyzing and integrating the large amounts of biological data it generates.

Lundbeck develops and markets drugs for treating central nervous system disorders, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, and insomnia.

"With our data-analysis capabilities and Lundbeck's expertise in the central nervous system area, we see a great synergy that has the potential to benefit patients with CNS related disorders," Intomics CEO Thomas Jensen said in a statement.

Financial terms of the agreement were not released.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.